Phoenixus AG, the drug company founded and controlled by Martin Shkreli, has maintained a low public profile following the backlash over the Daraprim price hike and his federal conviction for securities fraud.

While Shkreli has tried to steer Phoenixus’ operations from prison, the company formerly known as Vyera Pharmaceuticals (and Turing Pharmaceuticals before that) continues to lose money due to declining sales, according to financial documents obtained by STAT.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Phoenixus sounds like a quality employer . I feel bad about the rep who is battling cancer and dealing with job loss.

  • This figure is continually repeated – “and then raised the price on [Daraprim] more than 5,000%.” I am still waiting for a comment / report on what they are charging now. Remember they promised to cut the price?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy